Loss of the obscurin-RhoGEF downregulates RhoA signaling and increases microtentacle formation and attachment of breast epithelial cells
Metrics: PDF 1143 views | HTML 2116 views | ?
Nicole A. Perry1, Michele I. Vitolo2,3, Stuart S. Martin2,3 and Aikaterini Kontrogianni-Konstantopoulos1,3
1 Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD
2 Department of Physiology, University of Maryland School of Medicine, Baltimore, MD
3 Marlene and Stewart Greenebaum National Cancer Institute Cancer Center, University of Maryland School of Medicine, Baltimore, MD
Aikaterini Kontrogianni-Konstantopoulos, email:
Keywords: Breast cancer, metastasis, obscurin, actomyosin contractility, paclitaxel, circulating tumor cells, microtentacles
Received: June 27, 2014 Accepted: August 09, 2014 Published: August 10, 2014
Obscurins are RhoGEF-containing proteins whose downregulation has been implicated in the development and progression of breast cancer. Herein, we aim to elucidate the mechanism for increased motility of obscurin-deficient cells. We show that shRNA-mediated obscurin downregulation in MCF10A cells leads to >50% reduction in RhoA activity relative to scramble control (shCtrl), as well as decreased phosphorylation of RhoA effectors, including myosin light chain phosphatase, myosin light chain, lim kinase, and cofilin, in both attached and suspended cells. These alterations result in decreased actomyosin contractility, allowing suspended cells to escape detachment-induced apoptosis. Moreover, ~40% of shObsc-expressing cells, but only ~10% of shCtrl-expressing cells, extend microtentacles, tubulin-based projections that mediate the attachment of circulating tumor cells to endothelium. Indeed, we show that MCF10A cells expressing shObsc attach in vitro more readily than shCtrl cells, an advantage that persists following taxane exposure. Overall, our data suggest that loss of obscurins may represent a substantial selective advantage for breast epithelial cells during metastasis, and that treatment with paclitaxel may exacerbate this advantage by preferentially allowing obscurin-deficient, stem-like cells to attach to the endothelium of distant sites, a first step towards colonizing metastatic tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.